AJCC 8th Edition of Lung Cancer Staging: Emphasis on Multiple Lung Carcinomas
In the 8th edition of the American Joint Committee on Cancer (AJCC) lung cancer staging manual, several changes have been introduced, primarily affecting the T descriptor. These changes revolve around the introduction of adenocarcinoma in situ, minimally invasive adenocarcinoma, and adenocarcinoma with predominant lepidic pattern in the last World Health Organization’s classification of lung tumors. Furthermore, a special subcommittee of the International Association for the Study of Lung Cancer was formed to address ambiguity and problems of classifying and staging multiple lung tumors. These new concepts will be reviewed in this presentation.
Marie Christine Aubry, M.D.
Professor of Laboratory Medicine and Pathology
Mayo Clinic, Rochester, Minnesota
1. Describe the new T descriptors, especially as they pertain to sub-solid tumors.
2. Discuss how the staging of multiple lung carcinomas varies with the clinical scenarios.
3. Recognize the different clinical scenarios and the related staging scheme.
4. Review the importance and limitations of a pathologist’s interpretation in staging multiple lung carcinomas.
5. Explain the role and limitations of ancillary studies in distinguishing independent primaries from intrapulmonary metastasis.
This webinar is designed for pathologists.
Level of instruction
Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.
National Physician Payment Transparency Program
This webinar is designed for Mayo Medical Laboratories is not an applicable manufacturer or applicable group purchasing organization (GPO). (GPOs, per the Centers for Medicare & Medicaid Services, and this program do not trigger any reporting requirements pursuant to Open Payments [Sunshine Act] legislation.)
Note: No credit is offered for this Specialty Testing presentation.